Developing a process around the formulation Effective process development begins with an understanding of the formulation and its critical quality attributes. During pharmaceutical formulation development, candidate compositions are evaluated for characteristics such as API stability, drug loading and release behavior. Process development builds on this knowledge by investigating how manufacturing operations influence those characteristics. The objective is not simply to reproduce a laboratory procedure at a larger batch size. Equipment, mixing conditions, processing time and material handling can affect the properties of the resulting dosage form. For peptides and biologics, process selection must also account for molecular sensitivity. Conditions that are compatible with one API may not be suitable for another, making molecule-specific evaluation essential. Key considerations in pharmaceutical process development Process development involves identifying the parameters that influence product quality and determining how they can be controlled. The relevant parameters depend on the API, formulation technology and manufacturing method. Process consideration Why it matters Material attributes Variability in API, polymer or other starting materials may influence formulation and processing behavior. Mixing and processing conditions Changes in mixing intensity, temperature or processing time may affect product characteristics. Dosage form formation Particle formation, gel structure or other formulation-specific operations influence critical physical attributes. API integrity Processing conditions must be evaluated for their potential effects on molecular stability. Process reproducibility Repeated batches must be assessed for consistency in relevant product attributes. Scalability Changes in equipment or batch size may require adjustments to processing parameters and controls. Process development for long-acting injectables Manufacturing conditions are particularly relevant to sustained-release dosage forms because physical characteristics established during processing can influence subsequent API release. For microsphere-based formulations, process parameters may affect particle size distribution, morphology, drug loading and API distribution within the polymer matrix. These attributes can influence water penetration and release behavior. Other dosage forms introduce different requirements. Injectable gels and in situ forming depots may require investigation of viscosity, formulation preparation and handling characteristics, while solid implants have their own processing and dimensional considerations. Within long-acting injectable development, the selected process must therefore be evaluated alongside the formulation’s target release profile and other relevant quality attributes. Understanding critical process parameters Not every manufacturing parameter has the same influence on product quality. Process development investigates which material attributes and operating conditions are associated with meaningful changes in the finished formulation. Depending on the process, relevant parameters may include mixing speed, temperature, processing time, material concentration or conditions used during dosage form formation. Structured experiments can help establish relationships between these parameters and critical quality attributes. For example, changes in microsphere processing conditions may alter particle size distribution, which may in turn affect release behavior. Identifying these relationships provides a basis for defining suitable operating conditions and developing an appropriate process control strategy. Parameters should only be classified as critical when supported by the relevant process understanding and evidence. Discuss your process development requirements Contact Innocore Analytical testing and process reproducibility Analytical characterization is essential for evaluating whether process changes affect product quality. Depending on the formulation, testing may include API content, molecular integrity, particle characteristics, residual solvents or in vitro release behavior. Through analytical development, methods can be established to evaluate relevant attributes and compare material produced under different processing conditions. Reproducibility studies help determine whether a process can consistently produce formulations with the required characteristics. These studies may reveal sources of variability that are not apparent from individual laboratory experiments. Analytical evidence therefore supports both process optimization and decisions about readiness for subsequent manufacturing development. Preparing a process for scale-up Scaling a pharmaceutical manufacturing process involves more than increasing the quantity of starting materials. Changes in equipment geometry, mixing behavior, heat transfer or processing time can influence the resulting formulation. For polymer-based systems, these changes may affect matrix structure, API distribution and other attributes relevant to sustained release. Scale-up studies investigate how processing conditions should be adapted while maintaining the intended product characteristics. The appropriate scale-up strategy depends on the dosage form and manufacturing method. A microsphere process, for example, introduces different considerations from the preparation of an injectable gel. Evaluating scalability during process development helps identify limitations before a program advances to larger-scale manufacturing. From process development to technology transfer As a manufacturing process becomes better understood, relevant knowledge must be documented to support subsequent development and manufacturing activities. This may include material specifications, processing instructions, equipment requirements, analytical methods, identified process parameters and relevant product quality attributes. Technology transfer connects this development knowledge with the requirements of the receiving manufacturing environment. The scope of transfer depends on the process, equipment, development stage and applicable quality requirements. Innocore’s broader CDMO services connect process development with formulation, analytical and manufacturing capabilities, allowing process considerations to be addressed within the context of the overall development program. Frequently asked questions about pharmaceutical process development What is pharmaceutical process development? + Pharmaceutical process development involves designing and evaluating the manufacturing operations required to produce a formulation with defined quality attributes. It includes investigating processing parameters, reproducibility and potential scalability. How does process development differ from formulation development? + Formulation development focuses on the composition and characteristics of a dosage form. Process development focuses on how that formulation is manufactured and how processing conditions influence product quality. Why is process development important for long-acting injectables? + Processing conditions can influence dosage form structure, API distribution and release behavior. Process development investigates these relationships to support reproducible formulation performance. When should scale-up be considered? + Scale-up requirements should be considered during formulation and process development. Early evaluation can help identify manufacturing constraints before a formulation progresses to larger batches. Discuss your process development requirements Developing a reproducible manufacturing process requires an understanding of formulation characteristics, API stability, processing conditions and analytical evidence. Innocore supports pharmaceutical and biotechnology companies investigating process development and scale-up approaches for polymer-based sustained-release formulations. Contact Innocore to discuss the process requirements and manufacturing challenges of your development program. Contact Innocore